Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GAP FILLED!!!!!!................
Time to buy?
GO VCNX
"PEACE"
Meanwhile, on the other-side of Tesla, Inc......ENERGY!
Tesla's Megapack powers its small, but growing energy storage business
https://finance.yahoo.com/news/teslas-megapack-powers-small-growing-012144748.html
GO TESLA, INC
"PEACE"
$$$$$$ $$$$$$
AMADEINAMERICA , INTERNATIONALENERGYTECHNOLOGYANDCARCOMPANY
SAIC Awarded $89 Million Contract for IT Support and C4I Services to U.S. Army
https://finance.yahoo.com/news/saic-awarded-89-million-contract-111500016.html
GO SAIC
"PEACE"
Tesla has broken ground on its controversial German Gigafactory — take a look at how the site looks now
https://www.yahoo.com/news/tesla-broken-ground-controversial-german-195516853.html
AND........................
Secret Tesla Project To Bring Revamped Model S, X: Electrek
https://www.yahoo.com/news/secret-telsa-project-bring-revamped-153814074.html
WHILE...................
Starlink: Elon Musk's latest scheme to offer Internet via satellites
https://www.yahoo.com/news/starlink-elon-musks-latest-scheme-offer-internet-via-114933386.html
WITH.....................
Tesla share rally propels some early fan investors to riches
https://www.yahoo.com/news/tesla-share-rally-propels-early-172151644.html
GO TESLA, INC
"PEACE"
$$$$$$ $$$$$$
AMADEINAMERICA , INTERNATIONALENERGYTECHNOLOGYANDCARCOMPANY
Tesla, Inc........Negative. Just news of.
Tesla RSI is lingering again in the overbought area above the 70 indicator................It will always be due for a pull back, in most cases, in this area.
GO TESLA, INC
"PEACE"
$$$$$$ $$$$$$
AMADEINAMERICA , INTERNATIONALENERGYTECHNOLOGYANDCARCOMPANY
Tesla To Debut In India By 2021, Expects Roth Capital's Irwin, Raises Price Target
https://www.yahoo.com/news/tesla-debut-india-2021-expects-110324831.html
GO TESLA, INC
"PEACE"
$$$$$$ $$$$$$
AMADEINAMERICA , INTERNATIONALENERGYTECHNOLOGYANDCARCOMPANY
Here's Why Inovio Is The Front-Runner In Developing a Coronavirus Vaccine
Vaccine development is not an all-or-nothing endeavor. INO-4800 can rake in hundreds of millions in revenue if approved, even if only partially successful.
Jul 14, 2020 at 7:39AM
As of July 12, the number of new cases of COVID-19 in the U.S. has surpassed 60,000 for the fifth day in a row. Unfortunately, this rise cannot be attributed to increases in testing. For most of last week, nearly 1,000 Americans died each day due to COVID-19, representing a 300% increase from the death rate just a week prior.
Hence, the need for a coronavirus vaccine becomes more dire day by day. One of the front-runners of this endeavor is Inovio Pharmaceuticals (NASDAQ:INO). While it's already returned 601% year-to-date, I think shares have the potential to rally even further due to the potential of its COVID-19 vaccine candidate.
In search of a coronavirus vaccine
The vaccine is called INO-4800 and works by injecting synthetic viral DNA into healthy individuals, causing their bodies' immune systems to develop protective antibodies against the SARS-CoV-2 virus. Inovio boasts that the vaccine was designed in just three hours after the genome for SARS-CoV-2 was published in February.
In May, the vaccine produced robust antibody and T-cell responses in mice and guinea pigs, and advanced to the phase 1/2 stage for human trials. At this stage, 40 healthy adult volunteers aged 18 to 50 received INO-4800 to study its safety and immunization potential. Participants received 1 mg or 2 mg doses four weeks apart.
Last month, an interim data release indicated that 94% -- or 34 out of 36 -- healthy volunteers who received INO-4800 demonstrated immunological response.
While this may initially seem like good news, it's actually neutral at best. For starters, the body will naturally produce antibodies against any foreign substances, and just because patients produced antibodies after being given a vaccine does not mean the antibodies have a therapeutic effect.
Unfortunately, Inovio did not disclose how many volunteers developed neutralizing antibodies (antibodies that actually block the activity of SARS-CoV-2) after being administered the experimental vaccine. Without this crucial metric, it is impossible to make any efficacy claims from the clinical trials. However, the company does plan to proceed to phase 2/3 clinical trials for INO-4800 sometime in the summer, putting it ahead of nearly 35 reputable competitors.
Why the stock is a strong buy
Inovio is a strong buy because of how low the bar is for approval of coronavirus vaccines. Currently, the U.S. Food and Drug Administration mandates that experimental COVID-19 vaccines demonstrate a 50% improvement against placebo for commercialization. Keep in mind that's 50% improvement relative to a dummy, not a 50% response rate in terms of developing neutralizing antibodies.
Hence, for the sake of argument, even if INO-4800 demonstrates it can immunize 20% of study participants compared with 2% of patients that took a placebo, then the vaccine would still be approved under the current FDA mandate. I think it is more than likely that at least some of the 94% of patients who took INO-4800 and developed an immunological response also experienced a neutralizing antibody response. At the end of the day, a vaccine that works partially is better than no vaccine, and can still save countless lives when given to seniors and the immunocompromised.
The market opportunity for a potential COVID-19 vaccine is vast. At an affordable price of $100 per shot, a company that commercializes its vaccine can rake in $1 billion in revenue by producing 10 million doses. Currently, Inovio has the capacity to manufacture up to 1 million doses by year-end.
With recent backing from the U.S. Department of Defense for INO-4800's development program, I think the rally is far from over for this $3.7 billion mid-cap company. Hence, growth investors in the biotech industry should definitely have Inovio in their portfolios.
https://www.fool.com/investing/2020/07/14/heres-why-inovio-is-the-front-runner-in-developing.aspx
GO INO
"PEACE"
Did Hedge Funds Make The Right Call On Science Applications International Corp (SAIC) ?
https://finance.yahoo.com/news/did-hedge-funds-call-science-221048431.html
SAIC WILL BE BACK, WITH AN IMPACT!
GO SAIC
"PEACE"
Elon Musk sets update on brain-computer interface company Neuralink for August 28
https://www.yahoo.com/finance/elon-musk-sets-brain-computer-125903330.html
Just one more to be apart of the growing Tesla, Inc. (TSLA)
GO TESLA, INC
"PEACE"
$$$$$$ $$$$$$
AMADEINAMERICA , INTERNATIONALENERGYTECHNOLOGYANDCARCOMPANY
Is There a Coronavirus Vaccine Yet?
Companies are testing COVID-19 vaccines right now -- if all goes smoothly, more than one may get to market at “warp
Jul 8, 2020 at 6:30AM
Coronavirus vaccines have been making headlines recently, but so far, they all remain merely candidates in various stages of development. Nearly 130 investigational vaccines are in preclinical studies, while 18 have entered testing in humans, according to the World Health Organization.
So if you're hoping to get a vaccine to protect yourself from contracting COVID-19, the illness caused by the novel coronavirus, you'll have to wait until at least one candidate completes late-stage trials and the U.S. Food and Drug Administration gives its maker the official nod to move forward with commercialization.
A person wearing a stethoscope and mask vaccinates a masked patient or volunteer.
Which companies are leading the coronavirus vaccine race?
A number of biotech and pharmaceutical companies are racing to develop an effective COVID-19 vaccine. Moderna (NASDAQ:MRNA), AstraZeneca (NYSE:AZN), Inovio Pharmaceuticals (NASDAQ:INO), Novavax (NASDAQ:NVAX), and Johnson & Johnson (NYSE:JNJ) are among the leaders. Here are a few details about their respective programs.
Moderna
Moderna's phase 1 and 2 trials are ongoing, and the company plans to begin a phase 3 study on as many as 30,000 participants this month. Moderna reported positive interim phase 1 data, saying participants produced binding and neutralizing antibodies at levels seen in recovered COVID-19 patients or above. Binding antibodies signal a pathogen to the immune system, but more importantly, neutralizing antibodies actually block infection. Neutralizing antibody results were only available for eight participants, so Moderna will have to show this trend in a much larger population as trials continue.
Moderna's data also applied to a younger patient group -- ages 18 to 55. In the coming weeks, Moderna must demonstrate the safety and efficacy of its vaccine in older patients. This is particularly significant because elderly people have been most vulnerable during the coronavirus pandemic. Moderna's vaccine uses messenger RNA to instruct the body's cells to produce proteins to protect against infection.
AstraZeneca
Moderna was the first to enter human trials with a vaccine candidate, but AstraZeneca recently slipped into the lead. AstraZeneca partnered with the University of Oxford this spring, and they're now testing their candidate in a phase 2/3 trial. This trial will enroll more than 10,000 people in the U.K., with the phase 2 part broadening to include a small number of volunteers in age groups five to 12, 56 to 69, and over 70. The phase 3 part of the study will examine the vaccine's efficacy in a large group of participants over age 18. Researchers also are conducting a phase 3 trial in Brazil.
AstraZeneca's vaccine candidate is made from a weakened adenovirus, from one of the virus families that can cause the common cold, and includes genetic material from COVID-19 that will help the body identify the pathogen and defend itself against infection. Researchers haven't yet released study data.
Inovio
Clinical-stage biotech Inovio recently announced positive phase 1 data for its COVID-19 vaccine. The company said 94% of the 36 participants age 18 to 50 demonstrated immune responses six weeks after two doses. Inovio said this was based on binding and neutralizing antibodies and T-cell immune responses, but the report didn't offer further details. The company plans to begin a phase 2/3 efficacy study this summer.
The Inovio vaccine is based on the company's DNA medicines technology. Inovio's Cellectra device injects circles of DNA called DNA plasmids into the body. Those plasmids have been reorganized to produce immune response.
Novavax
In late May, Novavax announced the enrollment of the first volunteers in the phase 1/2 trial of its vaccine candidate. Like AstraZeneca, the company chose a trial design that combines phases, to help advance the vaccine more quickly. The first part is enrolling 130 participants age 18 to 59 in Australia. The second part, in various countries including the U.S., will expand the age range.
Initial immune response and safety results are expected this month.
Johnson & Johnson
The big pharma company initially planned to begin testing its vaccine in humans this fall, but changed its plans, based on promising preclinical data. J&J now aims to begin a phase 1/2a trial later this month. This study will involve more than 1,000 volunteers age 18 through 55, as well as adults age 65 and older.
If all goes well with that study, J&J and the National Institute of Allergy and Infectious Diseases are discussing the possibility of starting a phase 3 trial earlier than planned as well.
When will a coronavirus vaccine be available?
The U.S. government aims to get a vaccine to the public by January with its program called Operation Warp Speed. As part of Operation Warp Speed, the Department of Health and Human Services offered as much as $483 million in support to Moderna, $1.2 billion to AstraZeneca, and $456 million to Johnson & Johnson.
Moderna says it's on target to deliver about 500 million doses per year, and possibly as many as 1 billion, by next year. Oxford researchers, referring to the AstraZeneca vaccine, said they'd have efficacy results from their phase 3 trial this fall in "the best-case scenario."
For all companies investigating vaccines, trial results will determine the final timeline. If all goes well, it's possible one or more companies may meet the government's goal. However, any headwinds could slow the process.
Could more than one company win the coronavirus vaccine race?
The biggest stock gain may go to the first company to cross the finish line, but that doesn't mean the game is over for all the other players. Considering the global need for a vaccine, there is room for more than one vaccine maker. And in the long run, the company with the best vaccine -- whether it's the first to market or not -- is likely to take market share.
In the meantime, as companies move closer to the final research stage, investors will keep a close eye on each bit of news. And this news is likely to be a catalyst for shares of these biotech and pharmaceutical companies in the coming months.
https://www.fool.com/investing/2020/07/08/is-there-a-coronavirus-vaccine-yet.aspx
GO INO
"PEACE"
Bearish Tesla analyst explains why shares could surge to $2,070
https://finance.yahoo.com/news/bearish-tesla-analyst-explains-why-shares-could-surge-to-2070-172016966.html?.tsrc=fin-notif
GO TESLA, INC
"PEACE"
$$$$$$ $$$$$$
AMADEINAMERICA , INTERNATIONALENERGYTECHNOLOGYANDCARCOMPANY
Major Holders Breakdown
2.69% % of Shares Held by All Insider
29.41% % of Shares Held by Institutions
30.22% % of Float Held by Institutions
163 Number of Institutions Holding Shares
https://finance.yahoo.com/quote/INO/holders?p=INO
GO INO
"PEACE"
US:INO / Inovio Pharmaceuticals, Inc. - Short Interest, Short Volume, Short Squeeze
Security INO / Inovio Pharmaceuticals, Inc. (45773H201)
Latest Market Date 2020-07-07
Short Volume 21,622,596
Market Volume 62,338,200
Short Volume Ratio 35%
Short Interest
Short Interest is the total number of open short positions of a security. A Short Squeeze is when a company with a high degree of short interest increases in price, which forces short sellers to "cover" their short interest buy buying actual shares, which in turn drives the price up even further.
Date Short Interest Days to Cover
No data available
Short Volume
INO / Inovio Pharmaceuticals, Inc. short volume is shown in the following chart. Short Volume is a data set that can be used to understand investor sentiment. When an investor makes a short sale, they do so with the belief that a security will decline in price. If the short sale volume increases as a percentage of the total volume, then that suggests a bearish (negative) sentiment by the market. If short sale volume decreases as a percentage of total volume, then that suggests a bullish (positive) sentiment.
https://fintel.io/ss/us/ino
GO INO
"PEACE"
Just a bit of common knowledge and insight....HAPPY TRADING and/or INVESTING.
GO INO
'peace'
GO INO......Many would agree that shorting is what takes a stocks share price to higher highers, especially when a company's has seemingly something of value to offer and/or potential beyond the negative chatter.
Stock Trading Strategy & Education
What is a Short (or Short Position)
A short, or a short position, is created when a trader sells a security first with the intention of repurchasing it or covering it later at a lower price. A trader may decide to short a security when she believes that the price of that security is likely to decrease in the near future. There are two types of short positions: naked and covered. A naked short is when a trader sells a security without having possession of it. However, that practice is illegal in the U.S. for equities. A covered short is when a trader borrows the shares from a stock loan department; in return, the trader pays a borrow-rate during the time the short position is in place.
In the futures or foreign exchange markets, short positions can be created at any time.
Key Takeaways
A short position refers to a trading technique in which an investor sells a security with plans to buy it later.
Shorting is a strategy used when an investor anticipates the price of a security will fall in the short term.
In common practice, short sellers borrow shares of stock from an investment bank or other financial institution, paying a fee to borrow the shares while the short position is in place.
1:34
Short Selling
Understanding Short Positions
When creating a short position, one must understand that the trader has a finite potential to earn a profit and infinite potential for losses. That is because the potential for a profit is limited to the stock’s distance to zero. However, a stock could potentially rise for years, making a series of higher highs. One of the most dangerous aspects of being short is the potential for a short-squeeze.
A short-squeeze is when a heavily shorted stock suddenly begins to increase in price as traders that are short begin to cover the stock. One famous short-squeeze occurred in October 2008 when the shares of Volkswagen surged higher as short-sellers scrambled to cover their shares. During the short-squeeze, the stock rose from roughly €200 to €1000 in a little over a month.
https://www.investopedia.com/terms/s/short.asp
I SMILE WHEN I SEE HEAVILY SHORTED STOCKS ON THE MOVE THAT I'VE GOT APART OF.!
GO INO
"PEACE"
.......ALWAYS HAVE, ALWAYS WILL
US:INO / Inovio Pharmaceuticals, Inc. - Short Interest, Short Volume, Short Squeeze
Fintel helps you track changes to important SEC filings
When a company makes a change in a quarterly filing, it's almost always significant (or they wouldn't change it). Tracking changes used to be nearly impossible. Fintel highlights changes between quarterly and annual filings so these changes are easily spotted.
Security INO / Inovio Pharmaceuticals, Inc. (45773H201)
Latest Market Date 2020-07-01
Short Volume 31,668,687
Market Volume 103,810,500
Short Volume Ratio 31%
https://fintel.io/ss/us/ino
GO INO
"PEACE"
RSI FELL BACK T0 LOW 50'S......Currently 60.98 on the rise
Lithium Prices Are Set To Rally
Irina Slav
June 30, 2020, 3:00 PM CDT
Lithium used to be a frequent headline-hogger when the EV revolution first began, with all sorts of analysts expecting the metal’s price to skyrocket as the world wanted in on emission-free vehicles. This hasn’t happened yet, and lithium has recently become just one more commodity to suffer a price slump because of the coronavirus, which appears to have hit demand for everything.
But things may be about to change.
Lithium prices are once again poised for a rally in the next few years, according to analysts, and this is because EV sales are expected to jump, driven by the so-called green recovery plans of, for now, the European Union.
At the moment, things are not good for EVs and, therefore, for lithium bulls. Sales of electric vehicles could crash by 43 percent this year, in line with the expected trends in overall car sales because of the pandemic. In January alone, sales of EVs in China took a 54-percent plunge amid the lockdown. In May, the latest month with data available, overall sales in the biggest EV market in the world registered a sharp rebound, with SUVs performing particularly well.
EVs, on the other hand, did not do that well: BYD, one of China’s largest carmakers, said its sales of electric cars had halved in May from a year earlier. This could be an instance of another effect of the pandemic. In the current economic circumstances, people become more guarded against adopting new technology, Wood Mackenzie analysts said earlier this year.
This is why governments will play a key role in driving demand for electric vehicles and, as a result, higher lithium prices. It is governments that can pass the legislation that would increase subsidies for electric vehicles. Germany and France are already planning to raise their EV subsidies to drive more purchases. Other European countries will stick to current subsidies as EVs will make up a large part of the EU’s so-called green recovery that would seek to promote renewable energy and electrification of the transport sector in post-crisis Europe.
As a result, the medium-term outlook for lithium is anything but grim. Demand for the metal will certainly contract this year, in line with demand for everything else, but it will begin recovering as soon as next year, analysts believe. By 2022, according to analysts from Citi, the price of lithium carbonate—the compound used in EV batteries—could soar by as much as 42 percent, to $7,200 per ton.
Swiss bank Credit Suisse, however, notes that it may take a while before government stimulus for EV sales begins to have an effect on said sales and, consequently, on lithium prices. Right now, there is plenty of lithium supply on the market and only when EV sales pick up substantially enough, will prices begin to change in any meaningful way.
Indeed, it may take a while for a lithium price rally to materialize because it is not just aversion to new technology that is stopping people from switching to an EV from an internal combustion engine car. It is also the plain fact that even with subsidies, EVs are expensive, and many of them are not yet profitable. This will change, and it may well change quickly. Car manufacturers, which have poured billions in electric powertrain production platforms, will start to ramp up production in response to hopefully greater demand. But if EVs remain prohibitively expensive for many at low lithium prices, there is the question of how well electric car makers will do on sales and profitability when lithium prices rise.
https://www.yahoo.com/news/lithium-prices-set-rally-200000480.html
Now if PEMIF could just get some "Lithium" out of the ground and to market?
"peace"
US:INO / Inovio Pharmaceuticals, Inc. - Short Interest, Short Volume, Short Squeeze
Fintel helps you track changes to important SEC filings
When a company makes a change in a quarterly filing, it's almost always significant (or they wouldn't change it). Tracking changes used to be nearly impossible. Fintel highlights changes between quarterly and annual filings so these changes are easily spotted.
[track changes]
Security INO / Inovio Pharmaceuticals, Inc. (45773H201)
Latest Market Date 2020-06-29
Short Volume 14,886,802
Market Volume 52,957,900
Short Volume Ratio 28%
https://fintel.io/ss/us/ino
GO INO
"PEACE"
US:INO / Inovio Pharmaceuticals, Inc. - Short Interest, Short Volume, Short Squeeze
Security INO / Inovio Pharmaceuticals, Inc. (45773H201)
Latest Market Date 2020-06-24
Short Volume 43,460,168
Market Volume 125,018,200
Short Volume Ratio 35%
Short Interest
Short Interest is the total number of open short positions of a security. A Short Squeeze is when a company with a high degree of short interest increases in price, which forces short sellers to "cover" their short interest buy buying actual shares, which in turn drives the price up even further.
Date Short Interest Days to Cover
No data available
Short Volume
INO / Inovio Pharmaceuticals, Inc. short volume is shown in the following chart. Short Volume is a data set that can be used to understand investor sentiment. When an investor makes a short sale, they do so with the belief that a security will decline in price. If the short sale volume increases as a percentage of the total volume, then that suggests a bearish (negative) sentiment by the market. If short sale volume decreases as a percentage of total volume, then that suggests a bullish (positive) sentiment.
https://fintel.io/ss/us/ino
GO INO
"PEACE"
US:INO / Inovio Pharmaceuticals, Inc. - Short Interest, Short Volume, Short Squeeze
Activist hedge funds
Track changes in holdings of activist hedge funds.
[hfh tracker]
Security INO / Inovio Pharmaceuticals, Inc. (45773H201)
Latest Market Date 2020-06-23
Short Volume 62,110,890
Market Volume 172,015,000
Short Volume Ratio 36%
https://fintel.io/ss/us/ino
GO INO
"PEACE"
Musk Urges Tesla Staff To 'Go All Out' Through End Of Q2: Report
Lending credence to the theory of a quarter-end wave boosting Tesla Inc's (NASDAQ: TSLA) performance, CEO Elon Musk is marshaling the troops for one last push that could buoy what is widely believed to be an otherwise weak quarter.
Musk's Rallying Cry: For many reasons, Tesla's execution worldwide is concentrated on the final week of the second quarter that ends June 30, Electrek reported, quoting an internal email sent by Musk to the electric vehicle manufacturer's employees.
"It is very important that we go all out through end of June 30 to ensure a good outcome. Wouldn't bring this up if not very important," Musk reportedly said in the email.
Tesla's Quarter: Tesla has contended with both supply and demand side disruptions in the quarter. The raging COVID-19 pandemic has forced consumers to tighten their purse strings, dimming the sales outlook for premium vehicles such as the ones sold by the company.
The company also had to halt production at its Fremont, California facility due to the lockdown enforced by Alameda County.
Operations at Tesla's Shanghai Gigafactory were halted briefly in May due to a shortage of components. The Shanghai outlet began normal operations just ahead of the second quarter following COVID-19 disruptions for much of January and February.
Early data points suggest weak sales performance across the U.S.
Tesla new car registrations for the April-May period fell 33% to 14,15 units in 24 markets that accounted for about 65% of the automaker's U.S. market, according to Dominion Enterprises' Cross-Sell report.
From around 550,000 deliveries estimated for 2020 ahead of the pandemic, Street estimates have come down to around 400,000 units.
At last check, Tesla shares were advancing 1.35% to $1,007.74.
GO TESLA, INC
"PEACE"
$$$$$$ $$$$$$
AMADEINAMERICA , INTERNATIONALENERGYTECHNOLOGYANDCARCOMPANY
Musk Announces Tesla Basic Autopilot Deal
https://www.yahoo.com/autos/musk-announces-tesla-autopilot-upgrade-180000779.html
AND..............
The Model S is the oldest Tesla vehicle still in production — but with a new range upgrade. Here's why it might still be the best.
https://www.yahoo.com/news/model-oldest-tesla-vehicle-still-123200165.html
WHILE.......
Tesla builds first 400-mile electric vehicle
https://www.yahoo.com/news/tesla-builds-first-400-mile-000000982.html
GO TESLA, INC
"PEACE"
$$$$$$ $$$$$$
AMADEINAMERICA , INTERNATIONALENERGYTECHNOLOGYANDCARCOMPANY
https://www.yahoo.com/autos/tesla-wants-break-ground-plant-205700195.html
MEANWHILE, on the other side of Tesla,Inc.........ENERGY!
Tesla's Solar Panels Just Got a Big Update
https://www.yahoo.com/news/teslas-solar-panels-just-got-201800564.html
GO TESLA, INC
"PEACE"
$$$$$$ $$$$$$
AMADEINAMERICA , INTERNATIONALENERGYTECHNOLOGYANDCARCOMPANY
European study links genes, blood type with risk of severe coronavirus infection
https://www.msn.com/en-us/health/health-news/european-study-links-genes-blood-type-with-risk-of-severe-coronavirus-infection/ar-BB15Df9U?li=BBnb7Kz&ocid=U507DHP
Bodes well, as news, for INO's if they can truly get their DNA relate IN-4800 COVID vaccine to work.
WE WILL SEE!
GO INO
"PEACE"
Pure Energy Minerals Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - June 8, 2020) - Pure Energy Minerals Limited (TSXV: PE) (OTCQB: PEMIF) (the "Company" or "Pure Energy") announces, subject to regulatory approval, that pursuant to an annual performance and compensation review, it has granted a total of 4,800,000 stock options (the "Options") to directors, officers and consultants of the Company to purchase common shares of the Company in accordance with its stock option plan. All of the Options vest quarterly in four equal tranches, with the first such vesting occurring upon issuance of the Options, are issued at an exercise price of C$0.05 per common share and expire five years from the date of issuance.
On behalf of the Board of Directors,
"Mary L. Little"
Director, Pure Energy Minerals Limited
CONTACT:
Pure Energy Minerals Limited (www.pureenergyminerals.com)
Email: info@pureenergyminerals.com
Telephone - 604 608 6611
Cautionary Statements and Forward-Looking Information
The information in this news release contains forward looking statements that are subject to a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated in our forward-looking statements. Factors that could cause such differences include: changes in world commodity markets, equity markets, costs and supply of materials relevant to the mining industry, change in government and changes to regulations affecting the mining industry. Forward-looking statements in this release may include future exploration and development on the CV Project. Although we believe the expectations reflected in our forward-looking statements are reasonable, results may vary, and we cannot guarantee future results, levels of activity, performance or achievements.
The Company does not undertake to update any forward-looking information, except as required by applicable laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/57422
"Pure Energy Minerals Grants Stock Options
[Newsfile]
Newsfile Corp.
,Newsfile•June 8, 2020
Vancouver, British Columbia--(Newsfile Corp. - June 8, 2020) - Pure Energy Minerals Limited (TSXV: PE) (OTCQB: PEMIF) (the "Company" or "Pure Energy") announces, subject to regulatory approval, that pursuant to an annual performance and compensation review, it has granted a total of 4,800,000 stock options (the "Options") to directors, officers and consultants of the Company to purchase common shares of the Company in accordance with its stock option plan. All of the Options vest quarterly in four equal tranches, with the first such vesting occurring upon issuance of the Options, are issued at an exercise price of C$0.05 per common share and expire five years from the date of issuance.
On behalf of the Board of Directors,
"Mary L. Little"
Director, Pure Energy Minerals Limited
CONTACT:
Pure Energy Minerals Limited (www.pureenergyminerals.com)
Email: info@pureenergyminerals.com
Telephone - 604 608 6611
Cautionary Statements and Forward-Looking Information
The information in this news release contains forward looking statements that are subject to a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated in our forward-looking statements. Factors that could cause such differences include: changes in world commodity markets, equity markets, costs and supply of materials relevant to the mining industry, change in government and changes to regulations affecting the mining industry. Forward-looking statements in this release may include future exploration and development on the CV Project. Although we believe the expectations reflected in our forward-looking statements are reasonable, results may vary, and we cannot guarantee future results, levels of activity, performance or achievements.
The Company does not undertake to update any forward-looking information, except as required by applicable laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/57422
https://finance.yahoo.com/news/pure-energy-minerals-grants-stock-133000988.html
"PEACE"
It would be great to know if we still have a deal with Tesla,Inc. inked in 2015?
Pure Energy Minerals Ltd. Announces Lithium Supply Agreement
https://finance.yahoo.com/news/pure-energy-minerals-ltd-announces-131500183.html
Below is a video and artist rendition of the functioning lithium extraction plant planned, and it innovative extraction technique.
https://www.b-tv.com/btv-episode-321/
Chinese Lithium Giant Agrees Three-Year Pact to Supply Tesla
China’s top producer of lithium, a metal used in electric-vehicle batteries, said it’s agreed a deal with Tesla Inc. to supply a fifth of its production to the vehicle maker, highlighting the push for supply pacts.
Tesla will designate its battery suppliers to buy lithium-hydroxide products from Ganfeng Lithium Co. and its unit, the Jiangxi-based company said in a filing to the Shenzhen exchange on Friday. The agreement runs from 2018 to 2020 and could be extended by three years, Ganfeng said. Its shares jumped.
Electric-vehicle producers including Elon Musk’s Tesla are pushing to secure supplies of lithium for batteries as investors and mining companies gauge the potential for growth in the industry. Still, the burgeoning market has been roiled in 2018 by price declines, and forecasts from some banks that a wave of new mining projects will outpace demand growth.
Announcements from Ganfeng on plans for its relationship with Tesla, as well as battery producer LG Chem Ltd., help signal the quality of its products to potential investors ahead of a planned initial public offering in Hong Kong, Nomura Holdings Inc. analyst Jamie Wang said in an email.
Earlier this week, Ganfeng announced an agreement to supply LG Chem between 2019-2025 under a supplementary contract, according to a separate filing. Its lithium compounds capacity may rise to 75,000 tons of carbonate equivalent at the end of this year, making the producer the industry’s second-largest, according to CRU Group research cited in its IPO prospectus.
Along with Wednesday’s deal, Ganfeng has now locked in the sector’s two biggest supply pacts, Simon Moores, managing director of London-based industry consultant Benchmark Mineral Intelligence, said by phone. “These deals are dwarfing the size of the entire lithium hydroxide market from only a couple of years ago,” Moores said from a Sydney forum.
Tesla may need as much as 28,000 tons of lithium hydroxide a year from late next year based on battery output at its Nevada facility reaching the equivalent of 35 gigawatt hours, according to Benchmark Mineral’s forecasts. The automobiles-to-energy storage producer this year sealed a deal to add lithium supply from early next decade from Australia’s Kidman Resources Ltd.
https://www.bloomberg.com/news/articles/2018-09-21/chinese-lithium-giant-agrees-three-year-pact-to-supply-tesla?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo
GO PEMIF
"PEACE"
Telsa,Inc…...AAAAAAAAAAAAand.
Tesla to $10,000 share? This billionaire market bull is banking on it
‘There’s 10 times more to go.’
That’s billionaire investor Ron Baron, in a CNBC interview on Tuesday, going full bull on his big position in Tesla TSLA, -3.86% as the stock approaches $1,000 a share.
“I told you a long time ago that I thought we would make 20 times our money in Tesla,” Baron went on to explain. “So far, we’ve made four times. I now think we’re gonna make double or triple again over the next five years and double or triple again over the next five years.”
Baron’s investment firm holds 1.6 million shares of Tesla at an average cost of $219.02 each, according to Baron Capital data cited in the CNBC story. He said he’s looking to add to his Tesla stake, which is currently valued at $1.5 billion as of Monday’s closing level.
Baron’s portfolio is up 8% to 9% this year, CNBC reported, and he’s adding to his positions in several companies in the belief that the market is in good shape going forward. At last check, the Dow Jones Industrial Average DJIA, +1.90% and S&P 500 SPX, +1.30% were trading lower while the Nasdaq Composite COMP, +1.01% was in the green.
https://www.marketwatch.com/story/tesla-10000-this-billionaire-stock-market-bull-is-banking-on-it-2020-06-09?siteid=yhoof2&yptr=yahoo
GO TESLA, INC
"PEACE"
$$$$$$ $$$$$$
AMADEINAMERICA , INTERNATIONALENERGYTECHNOLOGYANDCARCOMPANY
Tesla Model Y Deliveries Expand Beyond the U.S.
The rapid rollout highlights the electric-car maker's accelerated pace of execution.
In yet another signal that Tesla (NASDAQ:TSLA) is getting better at manufacturing, the company's March-launched Model Y crossover is already beginning an international expansion, starting with Canada. The first deliveries of the vehicle in the market started last week. The Model Y's rollout to the country following the first U.S. deliveries of the vehicle happened much faster than the time it took the Model 3 to first make its way to Canada, highlighting the electric-car maker's accelerated pace of execution.
Here's a closer look at Tesla's progress with bringing to market
In March, Tesla impressed investors when it began deliveries of its Model Y six months ahead of its original schedule. Making the rollout even more impressive, Tesla said in its first-quarter update that its just-launched Model Y managed to contribute to profits during the period, marking the first time ever that a new Tesla product was profitable in its first quarter.
Now Tesla is achieving another important milestone for the vehicle by delivering the first units in Canada about three months after it was launched. For Tesla's Model 3, it took about six months for the first deliveries to occur outside of the United States.
It's not too surprising that the Model Y has already made its way to Canada. The company said in its first-quarter update that, thanks to a "simplified and scalable approach to manufacturing," it was able to build more Model Y vehicles in its first quarter of production than it did in the first two quarters of Model 3 production during 2017.
The Model Y represents a major growth opportunity
It's difficult to overstate the importance of the Model Y to Tesla's business. CEO Elon Musk has indicated he believes the vehicle will eventually outsell the Model 3 -- and the automaker isn't wasting any time investing heavily in the vehicle's production capacity. Tesla said it currently has the installed production tooling to produce 400,000 Model 3 and Model Y units annually on a combined basis at its Fremont Factory alone. In addition, Tesla is already building Model Y production capacity at factories in Germany and Shanghai, with deliveries of the important vehicle slated to begin in both of those markets in 2021.
Longer-term, Musk has said he estimates Model Y deliveries could grow to as much as 1.25 million units annually. Of course, this ambitious view for Model 3 is likely several years out, if it ever does materialize. Nevertheless, when viewed next to the approximately 393,000 vehicles Tesla has delivered over the trailing 12 months, it quickly becomes clear how imperative the Model Y is to the company's growth story.
Investors may want to keep an eye on any commentary management provides on the ongoing production ramp-up and delivery rollout of Model Y in future quarterly updates.
https://www.yahoo.com/finance/m/e95654e0-012d-3214-955f-0962f72ecdc4/tesla-model-y-deliveries.html
GO TESLA, INC
"PEACE"
$$$$$$ $$$$$$
AMADEINAMERICA , INTERNATIONALENERGYTECHNOLOGYANDCARCOMPANY
EU wants to buy COVID-19 vaccines up front - unless they're made in America
ReutersJune 11, 2020, 9:18 AM CDT
By Francesco Guarascio
BRUSSELS (Reuters) - The European Commission is seeking a mandate from EU countries to buy promising COVID-19 vaccine candidates in advance from pharmaceutical firms, as long as they are not produced solely in the United States, officials said.
The EU executive wants to pay for up to six potential vaccines in deals where the makers would commit to providing doses when and if they become available.
It will ask EU health ministers at a video conference meeting on Friday to back the plan, which has been swiftly devised as the bloc fears it may not have access to enough shots should a vaccine be developed.
All vaccines in clinical trial this year are in principle eligible for advance purchases, but not those which are produced exclusively in the United States, because Washington has signalled it will not allow sales abroad before its own needs are met, the EU officials told a news conference.
"Sourcing from producers that would only have production capacity in the United States would not really be an option for us," one Commission official said, adding this would not guarantee that the shots are available for the EU population.
The Commission official said U.S. companies with production facilities in Europe could be eligible. Asked which companies could be excluded from EU deals, she said it was too early to say.
The plan would offer financial guarantees to pharmaceutical companies, which face big losses if their vaccines are not successful.
"We pay up front a significant part of the investment needed in exchange for a commitment from the pharmaceutical manufacturer to give us a vaccine when is available," the official told a news conference.
The purchase agreements would be financed with an EU emergency fund, which currently has a budget of 2.4 billion euros ($2.7 billion), officials said, confirming Reuters' earlier reports.
EU governments, which are negotiating deals with pharmaceutical companies on their own, could also provide extra funding, the official said. It is not clear whether the plan has the backing of EU member states, however.
As part of the plan, the Commission will also propose a temporary softening of regulatory requirements to develop vaccines that contain genetically modified organisms (GMOs), officials said, confirming an earlier Reuters report.
If backed by EU health ministers on Friday, the Commission will make formal proposals next week.
https://www.yahoo.com/news/eu-plans-advance-purchase-six-141816199.html
GO INO
"PEACE"
Institutional Ownership and Shareholders
INO / Inovio Pharmaceuticals, Inc. Institutional Ownership
Inovio Pharmaceuticals, Inc. (US:INO) has 274 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 43,986,287 shares. Largest shareholders include BlackRock Inc., Vanguard Group Inc, Wasatch Advisors Inc, VR Adviser, LLC, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Nikko Asset Management Americas, Inc., Sumitomo Mitsui Trust Holdings, Inc., IWM - iShares Russell 2000 ETF, VEXMX - Vanguard Extended Market Index Fund Investor Shares, and State Street Corp.
Inovio Pharmaceuticals, Inc. (US:INO) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%.
Institutional Put/Call Ratio
In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.
Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.
https://fintel.io/so/us/ino
GO INO
"PEACE"
https://finviz.com/quote.ashx?t=INO
Security INO / Inovio Pharmaceuticals, Inc. (45773H201)
Latest Market Date 2020-06-08
Short Volume 4,499,889
Market Volume 14,912,700
Short Volume Ratio 30%
https://fintel.io/ss/us/ino
GO INO
"PEACE"
If Tesla can bring its German factory online in 2020, it really will have revolutionized the auto industry
Tesla Shanghai
Tesla built a new factory in China is about year, and is planning an even faster process for another plant in Germany.
Tesla's expanding manufacturing footprint is rapidly giving it a presence in the world's three most important markets: the US, China, and Europe.
The biggest innovations in the auto industry haven't involved propulsion — from Henry Ford to Toyota to Tesla, they've been about production.
A few years back, I made a cheap joke about Tesla and CEO Elon Musk. And like a lot of cheap jokes, I quickly regretted it.
The company had run into trouble with a heavily automated assembly line for its new Model 3 sedan at its California factory. To solve the problem, the company erected an improvised line under a temporary structure in its parking lot. But Musk had said his dream of a robot factory would be an "alien dreadnought" — unrecognizable in its speed, organization, and efficiency. Compare to a traditional car plant, it would be unrecognizable.
Musk promised an alien dreadnought, I quipped. But we got a tent in the parking lot.
Of course, it quickly became apparent that the tented assembly line was the best solution to the immediate problem. And it worked: in 2019, Tesla delivered a record 250,000 cars, many of them Model 3s.
What the tent showed was that Tesla could work fast. That was even more in evidence with the company's Shanghai factory, the first to be constructed in China by a western carmaker that didn't involve a joint venture with a Chinese partner. Construction began in 2018 and by early 2020 and pre-coronavirus outbreak in Wuhan, "Gigafactory Shanghai" in Tesla parlance was rolling out vehicles.
Berlin or bust!
Tesla Germany factory
COVID-19 shut down production, but it has restarted. Last week, Bloomberg reported that Tesla intends to bring its next factory Gigafactory Berlin, online by the middle of 2021. That would, in the span of less than three years, give Tesla a manufacturing footprint in the world's three most important vehicle markets — the US, China, and Europe — with a second US auto plant under consideration to build the company's exotic Cybertruck pickup.
Tesla is building new factories at a pace that's about twice as fast as other carmaker have recently constructed facilities. Volvo's plant in South Carolina took about two years to start moving vehicles off the lines.
The potential here is borderline revolutionary because Tesla's Achilles' heel is supposed to be manufacturing competence. It certainly isn't customer loyalty, which is among the highest in the business, nor is it marketing skill — Tesla has become the most valuable US automaker by stock-market value, worth more than General Motors, Ford, and Fiat Chrysler Automobiles combined, by spending essentially nothing on advertising.
The German factory was supposed to be a challenge; it's one things to move fast in China, with a supportive government backing rapid industrial development, but it's something else to rapidly build in Europe, with its mesh of at times conflicting business, labor, political, and environmental interests.
But Germany appears to want Tesla sooner rather than later. And that isn't good news for the traditional German auto industry, which is currently struggling to deal with COVID-19 while also shifting to electrification without destroying its legacy business in the process. While the VW Group, for example, figures things out, Tesla could be putting rubber on the autobahn by 2021.
The most important innovation of the post-COVID world
tesla factory
It's becoming increasingly obvious that Tesla, with an all-electric, all-the-time approach to autos, is likely to emerge from the coronavirus crisis with a better head of EV steam than the legacy companies, if you'll excuse the mixed metaphor. The only real question is whether the EV market will recover, post-COVID, or stall out. And even if it stalls out, Tesla has a near monopoly at this point, so the upshot is that the competition would retire before the race even gets started.
As far as infrastructure goes, however, Tesla is consolidating its lead: more factories, faster than expected, supporting more production and satisfying whatever increased demand there is.
This demonstrates a vital but often forgotten lesson about the auto industry. It wasn't the Model T that created Henry Ford's fortune — it was the moving assembly line that enabled workers to rapidly build the car. It wasn't the Camry or Corolla that made Toyota the world's most valuable car company — it was the "Toyota Production System," the just-in-time manufacturing model that replaced Ford's earlier innovation. The entire industry has adopted TPS, which focuses of quality and matches production rates to market demand.
For Tesla, it's the gigafactories that matter, more than the vehicles. They might not be alien dreadnoughts. But they're a far cry from tents. And they're at the leading edge of a manufacturing revolution.
https://www.businessinsider.com/tesla-german-factory-online-2020-will-revolutionize-auto-industry-2020-6
GO TSLA
"PEACE"
Why You Shouldn’t Rush to Take Profits on Inovio Stock
,InvestorPlace•June 5, 2020
If there’s one thing that traders have learned about Inovio Pharmaceuticals (NASDAQ:INO) stock, it’s that half a year can make a huge difference. Biotechnology stocks can be fast movers, sure, but this particular one has been a real barn burner, as they say.
Why You Shouldn't Rush to Take Profits on INO Stock Yet
INO stock was trading for $3 and change at the beginning of this year, but a whole lot has happened since then. The spread of the novel coronavirus has put clinical-stage biotechnology companies like Inovio in the spotlight. And that’s enriched its stockholders while causing problems for short sellers.
The share price did ease off of the mid-May peak, but that’s not necessarily indicative of any actual problems with Inovio. For those traders who did choose to take profits on INO stock, they may soon find that they cut their winnings short and left a considerable amount of money on the table.
A Serious Contender
The race to develop a vaccine for the coronavirus is still in effect and it’s closely watched by the investing community. Each stage of progress in the development of a vaccine is likely to be rewarded by stock traders.
Among the contenders in the biotechnology space, Inovio is a strong candidate. It is working tirelessly in pursuit of the elusive coronavirus vaccine. A recent research study suggested potentially positive results for Inovio’s Covid-19 vaccine candidate, INO-4800. In this study, the vaccine candidate was tested on laboratory mice and guinea pigs.
Those preliminary findings aren’t the be-all and end-all, but they represent great progress for Inovio. By the end of this year, the company plans to have 1 million doses of INO-4800. It’s conceivable that Inovio could become a household name in 2020.
And a high-figure financial award could help Inovio’s plans come to fruition. Specifically, the Coalition for Epidemic Preparedness Innovations has given Inovio a total of $17.2 million. That’s a tremendous head start from a financial standpoint.
A Promising Partnership
Having access to the capital provided by the Coalition for Epidemic Preparedness Innovations will undoubtedly prove to be advantageous for Inovio. But a game-changing partnership between research-driven entities could give Inovio an even greater edge over the competition.
On June 4, the International Vaccine Institute and Seoul National University Hospital announced a headline-grabbing collaboration. Together, they will commence a Phase 1/2 clinical trial of INO-4800 in South Korea.
This event is already making history as this two-stage trial, which is scheduled to begin later in June, will be the first Covid-19 vaccine clinical study in Korea. At first, INO-4800 will be tested on 40 healthy adults ranging in age from 19 to 50 years.
After that, 120 more people, ranging in age from 19 to 64 years, will be enrolled in the study. Funding for this research will come from the Coalition for Epidemic Preparedness Innovations with support from the Korea Center for Disease Control and Prevention/Korea National Institute of Health.
This is an excellent example of fast-tracking in action. Usually it would take several years to begin clinical trials for a new vaccine. But since the need for a coronavirus vaccine is urgent, this INO-4800 study can start promptly.
International Vaccine Institute Director General Jerome Kim expressed eagerness to move forward with the trial. He called the INO-4800 research “a crucial step in the development of an urgently needed COVID-19 vaccine.”
Seoul National University Hospital Professor Myung Don Oh also emphasized the importance of the upcoming INO-4800 trial. He predicted that the trial “will provide significant momentum in easing fears over the pandemic and helping return to normalcy.”
The Final Word on INO Stock
The prospect of INO-4800 helping get the world get back to a more normal, healthy state is encouraging. INO stockholders should be encouraged by Inovio’s efforts to be first to market with a coronavirus vaccine. And they can view any share-price dips as temporary as the company’s progress should be reflected in the stock price soon enough.
https://finance.yahoo.com/news/why-shouldn-t-rush-profits-192151493.html
GO INO
"PEACE"
Is Moderna Really the Leader in the COVID-19 Vaccine Race?
Maybe, but maybe not.
https://www.fool.com/investing/2020/06/07/is-moderna-really-the-leader-in-the-covid-19-vacci.aspx
GO INO
"PEACE"
Overlooked Covid-19 Vaccine Runners Up Defended by Wall Street
,Bloomberg•June 4, 2020
(Bloomberg) -- Don’t give up hope for Novavax Inc. and Inovio Pharmaceuticals Inc., Wall Street analysts said after the two failed to appear on a Trump administration list of Covid-19 vaccine developers picked for Operation Warp Speed.
The pair slid more than 10% on Wednesday following a New York Times report saying that the White House’s list included larger drugmakers such as AstraZeneca PLC, Johnson & Johnson, Merck & Co. and Pfizer Inc., but not the pair of small-caps.
Bloomberg reporting shows that two other, as yet unnamed, companies have also been selected for the U.S. government’s effort. An official announcement is expected within weeks.
One analyst thought Inovio must be one of the missing finalists from the White House’s effort. “INO-4800 is more-than-likely on the short list of remaining vaccine candidates,” Stifel’s Stephen Willey wrote, pointing to safety and immunogenicity results expected by the end of the month as well as Inovio’s “competitive advantages.” The Plymouth Meeting, Pennsylvania-based company’s experimental vaccine, INO-4800, uses part of the virus’s DNA to trigger an immune response.
“WARP Speed finalists may not be final” and the initial list may be short-sighted, Cantor Fitzgerald analyst Charles Duncan said. “Show me the data,” he said, noting the vaccine developers mentioned were “high-profile, large pharma candidates, all of which lack significant clinical experience.”
Duncan expects that different approaches to developing an immunization against Covid-19 will be needed and saw both Inovio and Novavax’s candidates as good options, though neither has yet to commercialize a product. He gives Inovio and Novavax buy-equivalent ratings.
The two U.S.-based biotechs are each working on one of the 10 vaccines for Covid-19 currently being tested in humans, according to the World Health Organization. More than 120 others are being tested in animals. Also in the clinical stages of vaccine development, but not mentioned in the Bloomberg or N.Y.Times reports, are Chinese vaccine developers Sinovac Biotech Ltd., CanSino Biologics Inc. and SinoPharm Group Co., all three of whom are conducting human trials of vaccines.
Moderna Inc., another unproven vaccine developer that’s working on an RNA-based immunization, was selected. The Cambridge, Massachusetts-based biotech has been working with the National Institutes of Health since the start of the pandemic and is already backed by more than $400 million in federal funding. One problem with Moderna’s and other rival’s methods will be cold storage and finding enough facilities to house their vaccines. That’s not a problem for Novavax’s protein based approach or Inovio’s DNA-based platform, Cantor’s Duncan said.
Novavax is not without backers. The biotech secured $388 million in May, the single largest grant from the Coalition for Epidemic Preparedness Innovations (CEPI) at the time. Inovio has received $17 million from the Oslo-based group.
Another blow to confidence in untested vaccine developers came on Thursday after AstraZeneca secured $750 million from CEPI and Gavi, the Vaccine Alliance, a non-profit organization.
Prominent makers of vaccines such as Sanofi and GlaxoSmithKline Plc, were also notably absent from the White House list. Operation Warp Speed is headed up by Moncef Slaoui, a former Glaxo executive.
Inovio fell as much as 4.3% Thursday. Novavax rose as much as 5.5% before paring most of those gains.
https://finance.yahoo.com/news/overlooked-covid-19-vaccine-runners-184200744.html
GO INO
"PEACE"
WE WILL SEE
INO.....I-NO
Hence the most reasonable reason for the drop today. Someone(s) had knowledge of these developments ahead of general retail.
https://www.fool.com/investing/2020/06/03/why-inovio-pharmaceuticals-stock-sank-today.aspx?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article&yptr=yahoo
STILL GOOD & GREEN
GO INO
"PEACE"
Institutional and Fund Ownership - Buyers
Major holders that have opened new positions in INO / Inovio Pharmaceuticals, Inc. include VR Adviser, LLC, Jane Street Group, Llc, JP Morgan Chase & Co, Oz Management LP, Ikarian Capital, LLC, Oz Management LP, PCSGX - PACE Small/Medium Co Growth Equity Investments Class P, Oz Management LP, Ifg Advisory, Llc, PSGIX - Blackrock Advantage Small Cap Growth Fund Institutional, Css Llc/il, Advisor Group Holdings, Inc., Bank Julius Baer & Co. Ltd, Zurich, Summit Wealth & Retirement Planning, Inc., PEXMX - T. Rowe Price Extended Equity Market Index Fund, Strategic Wealth Management Group, Llc, ETRADE Capital Management LLC, Cnh Partners Llc, Seacrest Wealth Management, Llc, and GONIX - Gotham Neutral Fund Institutional Class.
https://fintel.io/sob/us/ino
GO INO
"PEACE"
Better Coronavirus Stock: Moderna or Inovio Pharmaceuticals?
The coronavirus vaccine race offers these clinical stage companies an opportunity to bring a first product to market -- if all goes well in human trials.
From a timeline perspective, Moderna (NASDAQ:MRNA) and Inovio Pharmaceuticals (NASDAQ:INO) are close rivals in the race to develop a vaccine for COVID-19. Moderna was the first to start human trials in March, and Inovio began its human trial less than a month later.
Both stocks have skyrocketed since the start of the year. Moderna has soared 182%, while Inovio has jumped 304% as investors bet on their coronavirus vaccine programs.
Vials of vaccine are positioned on a glass table.
But which of the two is the best coronavirus stock to buy? Let's take a closer look.
The pipelines
Moderna and Inovio are both clinical stage biotech companies, meaning they haven't yet brought a product to market. Besides the COVID-19 vaccine, Moderna's most advanced product is in phase 2 testing. The company has more than 20 candidates in the pipeline for indications including influenza, Zika, and various types of cancer.
Moderna's technology involves harnessing the power of messenger RNA (mRNA). The investigational products use messenger RNA to give the body's cells instructions to make proteins that would prevent or treat disease.
Inovio has about 15 candidates in the pipeline, most of which are in phase 2 testing. The company develops medicines for infectious diseases and cancer. Inovio's lead candidate is currently in phase 3 trials for precancerous cervical dysplasia, and the company plans on reporting top-line efficacy data in the fourth quarter.
Inovio's treatments involve the use of optimized DNA plasmids. Through computer sequencing, these small circles of double stranded DNA are reorganized to produce a specific immune response in the body. Inovio then delivers these plasmids intradermally or intramuscularly through the company's own handheld smart device.
The coronavirus programs
As the U.S. government has vowed to help accelerate the development of a coronavirus vaccine, Moderna and Inovio have an opportunity to bring a product to market sooner than they would have in pre-coronavirus times. That is, if all goes well in clinical trials.
So far, Moderna is a step ahead in terms of timeline and funding. The company recently reported interim data from its phase 1 trial involving 45 healthy volunteers. Results on neutralizing antibodies, or those that stop infection, were only available for a total of eight people. In those participants, neutralizing antibodies were at or above levels of those of recovered coronavirus patients.
That is promising, but before getting too excited, we should wait to see if the trend is the same across all participants. The U.S. Food and Drug Administration gave Moderna the nod to start a phase 2 trial involving 600 participants, and a phase 3 trial is expected to start in July.
As for funding, the U.S. Department of Health and Human Services (HHS) recently granted Moderna as much as $483 million. That's enough to carry the vaccine through regulatory approval and support a scale-up in manufacturing, Moderna said.
Inovio's phase 1 study in 40 healthy volunteers is set to report preliminary data on safety and immune response in late June. The company said preclinical studies have shown "robust" neutralizing antibody and T cell immune responses. Inovio plans on beginning a phase 2/3 efficacy study in July or August if all goes well in the earlier trial.
Inovio's biggest award comes from the Coalition for Epidemic Preparedness Innovations. The global organization to accelerate vaccine development has awarded Inovio more than $17 million for its COVID-19 program.
Which stock to choose?
Moderna's and Inovio's pipelines are based on mRNA and DNA technology, respectively. That means victory in the coronavirus program not only opens the door to commercialization of a product, but also offers evidence of those technologies' efficacy in humans. That could be a big step forward for both companies.
At this stage, it's impossible to say which company will win this race to find a vaccine -- or even make it to the finish line. During clinical trials, anything can happen at any point. And share gains have been significant, pushing Moderna and Inovio prices above Wall Street's average estimates by 47% and 6%, respectively. For these two reasons, investment in Moderna and Inovio should be done with extreme caution.
That said, if I had to choose between the two biotech stocks, I would favor Moderna because it offers a bit more visibility. The company has started to deliver some human data, and so far, the results have been encouraging. And the amount of government funding is another plus, meaning Moderna may not stumble financially to bring this potential product to market.
https://www.fool.com/investing/2020/05/31/better-coronavirus-stock-moderna-or-inovio-pharmac.aspx
"PEACE"
Market Date Short Volume Total Volume Short Volume Ratio
2020-05-28 4,344,730 13,864,600 31.34
2020-05-27 7,781,628 25,674,400 30.31
2020-05-26 5,833,075 20,717,300 28.16
2020-05-22 5,294,254 16,171,700 32.74
2020-05-21 10,624,225 34,343,000 30.94
2020-05-20 21,671,194 77,201,100 28.07
2020-05-19 8,559,747 33,146,600 25.82
2020-05-18 10,550,733 35,477,500 29.74
2020-05-15 6,480,926 22,126,400 29.29
2020-05-14 8,893,630 30,107,400 29.54
"PEACE"